News >

Quest Continues to Extend Reach of Immunotherapy, PARP Inhibitors in Ovarian Cancer

Caroline Seymour
Published: Wednesday, Jul 17, 2019

Matthew Powell, MD

Matthew Powell, MD

Single-agent immunotherapy has elicited minimal responses in patients with ovarian cancer, but the preclinical rationale for combinations with chemotherapy, antivascular therapy, and PARP inhibitors is strong and worthy of further pursuit, said Matthew Powell, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x